HC Wainwright Issues Pessimistic Estimate for UTHR Earnings

Key Points

• HC Wainwright has downgraded its Q3 2025 earnings per share estimate for United Therapeutics from $7.03 to $6.54, while maintaining a "Buy" rating with a price target of $400.00.
• United Therapeutics reported a Q2 earnings per share of $6.41, missing the consensus estimate of $6.80 and generating quarterly revenue of $798.60 million, which was below expectations.
• Analysts have lowered price targets for United Therapeutics, with Morgan Stanley reducing its target from $348.00 to $328.00, indicating a cautious outlook for the company in the near term.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Investment analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for shares of United Therapeutics in a research note issued on Thursday, July 31st. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $6.54 for the quarter, down from their previous forecast of $7.03. HC Wainwright has a "Buy" rating and a $400.00 price objective on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics' Q4 2025 earnings at $6.44 EPS and FY2025 earnings at $26.02 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.85 EPS.

Several other equities analysts have also recently weighed in on UTHR. Morgan Stanley cut their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. UBS Group dropped their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a report on Monday, June 30th. Bank of America dropped their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. JPMorgan Chase & Co. dropped their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Finally, Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $379.69.

United Therapeutics Price Performance

NASDAQ UTHR opened at $294.28 on Monday. The stock has a market capitalization of $13.27 billion, a PE ratio of 11.49, a P/E/G ratio of 4.43 and a beta of 0.57. The business has a 50 day simple moving average of $298.13 and a two-hundred day simple moving average of $312.88. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. LPL Financial LLC raised its position in United Therapeutics by 122.8% during the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock valued at $5,024,000 after purchasing an additional 7,847 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in United Therapeutics by 6.2% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company's stock valued at $1,387,000 after purchasing an additional 228 shares in the last quarter. World Investment Advisors raised its position in United Therapeutics by 18.4% during the 4th quarter. World Investment Advisors now owns 1,299 shares of the biotechnology company's stock valued at $458,000 after purchasing an additional 202 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in United Therapeutics during the 4th quarter valued at $1,899,000. Finally, Resona Asset Management Co. Ltd. bought a new stake in United Therapeutics during the 4th quarter valued at $6,902,000. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $11,185,469.91. This trade represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 70,681 shares of company stock valued at $21,318,359 over the last quarter. 10.30% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.